Engineers Gate Manager LP Purchases 104,729 Shares of Zoetis Inc. $ZTS

Posted by Stanley Muller on Sep 11th, 2026

Engineers Gate Manager LP lifted its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 3,551.3% during the second quarter, Holdings Channel reports. The institutional investor owned 107,678 shares of the company’s stock after purchasing an additional 104,729 shares during the period. Engineers Gate Manager LP’s holdings in Zoetis were worth $7,738,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. California State Teachers Retirement System raised its holdings in Zoetis by 6,680.3% during the second quarter. California State Teachers Retirement System now owns 47,745,365 shares of the company’s stock valued at $3,430,982,000 after acquiring an additional 47,041,186 shares during the period. J. Stern & Co. LLP boosted its stake in shares of Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares during the period. Norges Bank bought a new position in shares of Zoetis in the fourth quarter worth about $734,425,000. Flossbach Von Storch SE purchased a new stake in shares of Zoetis during the second quarter worth about $302,601,000. Finally, BlackRock Inc. grew its position in shares of Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.4%

Shares of ZTS stock opened at $73.00 on Friday. Zoetis Inc. has a 12-month low of $71.00 and a 12-month high of $152.00. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The stock’s 50-day moving average price is $75.60 and its 200-day moving average price is $92.10. The stock has a market capitalization of $30.16 billion, a price-to-earnings ratio of 12.03, a price-to-earnings-growth ratio of 1.71 and a beta of 0.73.

Zoetis (NYSE:ZTS – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the previous year, the business earned $1.76 earnings per share. The firm’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities research analysts predict that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Zacks Research downgraded Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Stifel Nicolaus cut their price objective on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a report on Thursday, August 20th. UBS Group reduced their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. BNP Paribas Exane reduced their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. Finally, Argus reissued a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and an average target price of $101.08.

View Our Latest Analysis on ZTS

Zoetis Company Profile

(Free Report)

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.